Anti-HLA antibodies monitoring in patients with chronic renal failure on waiting list for renal transplant in Paraguay
Abstract
Introduction: Anti-HLA antibodies determination in the serum of patients on a waiting list for renal transplant is essential to optimize donor selection as well as for the induction and maintenance immunosuppression scheme, according to immunological risk. These antibodies could be present before transplantation as a result of being exposed to blood transfusions, pregnancies and previous transplants. The objective of the study was to determine immunization against HLA antigens, associated factors and their impact on the waiting list for a renal transplant. Methods: In this observational retrospective cross sectional study, 254 patients on the waiting list for renal transplant were included. These patients attended the Public Health central laboratory between July 2013 and July 2015. Results: 30% of the 254 studied patients presented anti-HLA antibodies. The most significant sensitizing event was the exposure to a previous transplant (p=<0.05). Multiparous women were in second place, 69% of them presenting positive PRA (panel reactive antibodies) (p=<0.05). Finally 24% of poly transfused patients presented anti-HLA antibodies (p=<0.05). Conclusions: During the 2 year of the study, 51 patients were transplanted, presenting only one of them anti-HLA antibodies before transplantation. This results clearly indicate that the immunization against HLA represents a barrier for transplantation access.
References
Tonelli M, Wiebe N, Knoll G, Bello A, Browne S, Jadhav D, et al. Systematic review: kidney transplantation compared with dialysis in clinically relevant outcomes. Am J Transplant. 2011;11(10):2093-109.
Matas AJ, Smith JM, Skeans MA, Thompson B, Gustafson SK, Schnitzler MA, et al. OPTN/SRTR 2012 Annual Data Report: kidney. Am J Transplant. 2014;14 Suppl 1:11-44.
Cicora F, Mos F, Roberti J. Trasplante renal en pacientes con anticuerpos dirigidos contra donante. Medicina (B. Aires). 2014; 74(5): 400-3.
Puttarajappa C, Shapiro R, Tan HP. Antibodymediated rejection in kidney transplantation: a review. J Transplant. 2012;2012:193724.
Loupy A, Lefaucheur C, Vernerey D, Prugger C, Duong van Huyen JP, Mooney N, et al. Complement-binding anti-HLA antibodies and kidney-allograft survival. N Engl J Med. 2013;369(13):1215-26.
Galeas RA, Gomezchico-Velasco R, Valverde S, García GR, Velásquez-Jones L, Romero-Navarro B, et al. Anticuerpos anti-HLA y rechazo agudo del injerto renal en los niños. Bol Med Hosp Infant Mex. 2010;67(6):492-502.
Marfo K, Lu A, Ling M, Akalin E. Desensitization protocols and their outcome. Clin J Am Soc Nephrol. 2011;6(4):922-36.
Mancilla–Urrea E. El paciente altamente sensibilizado.
Alternativas terapéuticas para el trasplante renal. Rev Invest Clín. 2005;57(2):206-12.
Toledo N, Tiscornia A, Bengochea M, Carrettoá E, Silva E, Cabrera A., et al. Monitoreo de anticuerpos HLA en insuficientes renales crÛnicos en lista de espera uruguaya para trasplante renal 2005. Rev Med Uruguay. 2008;24(1):15-23.
Scornik JC, Bromberg JS, Norman DJ, Bhanderi M, Gitlin M, Petersen J. An update on the impact of pre-transplant transfusions and allosensitization on time to renal transplant and on allograft survival. BMC Nephrol. 2013;14:217.
De–Leo–Cervantes C. Pruebas de Histocompatibilidad en el Programa de Trasplantes. Rev Invest Clín. 2005; 57(2): 142-6.
Brito-García A, Gutiérrez-García F, Trujillo-Álvarez Y, Peña-Fresneda N, Barberia-Torres D, Díaz-Báez N. Anticuerpos anti-HLA en pacientes con insuficiencia renal crónica en espera de trasplante renal. Rev Cubana Hematol Inmunol Hemoter. 2012;28(3):275-81.
Prieto F, Cabañas C, Villagra V. Características de los pacientes en espera de trasplante renal. Mem Inst Investig Cienc Salud. 2015;13(1):49-57.
Dmbrausky Osowski L, Gutierrez M, Muth B. HLA Antibody screening and identification by ELISA Methodology. En: Hahn A, Land G, Strothman R ed. American Society for Histocompatibility and Inmuno-genetics Laboratory Manual. 4th ed. Lenexa, KS: ASHI: 2000. Vol. 1, p. I.D.2.1-11.
Organ Procurement and Transplantation Network [Internet]. Policy 8: Allocation of Kidneys. En: OPTN Policies, 2016, p. 74-94. Disponible en: http://optn.transplant.hrsa.gov/ContentDocuments/OPTN_Policies.pdf
Scornik JC, Meier-Kriesche HU. Blood transfusions in organ transplant patients: mechanisms of sensitization and implications for prevention. Am J Transplant. 2011;11(9):1785-91.
Lima BA, Mendes M, Alves H. Hypersensitized candidates to kidney transplantation in Portugal. Port J Nephrol Hypert. 2013;27(2):77-81.
Jordan SC, Pescovitz MD. Presensitization: the problem and its management. Clin J Am Soc Nephrol. 2006;1(3):421-32.
Lefaucheur C, Loupy A, Hill GS, Andrade J, No chy D, Antoine C, et al. Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. J Am Soc Nephrol. 2010;21(8):1398-406.
Colombo MB, Haworth SE, Poli F, Nocco A, Puglisi G, Innocente A, et al. Luminex technology for anti-HLA antibody screening: evaluation of performance and of impact on laboratory routine. Cytometry B Clin Cytom. 2007;72(6):465-71.
Eng HS, Bennett G, Bardy P, Coghlan P, Russ GR, Coates PT. Clinical significance of anti-HLA antibodies detected by Luminex: enhancing the interpretation of CDC-BXM and important post-transplantation monitoring tools. Hum Immunol. 2009;70(8):595-9.
Worsley CM, Mayne ES, Suchard MS. Luminexbased virtual crossmatching for renal transplantation in South Africa. S Afr Med J. 2011;102(1):40-3.
